A+ | A | A- | Skip to main content |

Sensex

Nifty

USDINR

GBPINR

EURINR

Thursday, 04 June 2026 12:00 AM EOD	Asian-Paints2661.70	Hind-Unilever2078.10	ITC280.30	Trent2837.30	Larsen-and-Toubro3939.50	M-and-M3014.85	Reliance-Industries1304.20	Tata-Steel210.55	Titan-Company4226.95	SBI979.65	Bharat-Electron409.90	Kotak-Mah-Bank381.35	Infosys1200.65	Bajaj-Finance873.90	Sun-PharmaInds1779.35	HDFC-Bank754.55	TCS2239.60	ICICI-Bank1252.30	Power-Grid-Corpn284.65	Maruti-Suzuki13058.10	Axis-Bank1252.40	HCL-Technologies1168.50	NTPC366.35	Bharti-Airtel1818.35	Tech-Mahindra1487.00	Adani-Ports1790.50	UltraTech-Cem10995.55	Bajaj-Finserv1709.95	Interglobe-Aviat4503.30	Eternal254.30
15 mins delay SENSEX 74,360.01 [13.84]	1.95 0.07%	-13.05 -0.62%	3.35 1.21%	-1.43 -0.05%	-14.40 -0.36%	3.90 0.13%	-8.85 -0.67%	-1.25 -0.59%	140.35 3.43%	8.65 0.89%	3.15 0.77%	0.00 0.00%	-21.55 -1.76%	-2.65 -0.30%	-10.10 -0.56%	0.90 0.12%	-2.10 -0.09%	9.95 0.80%	-0.50 -0.18%	4.20 0.03%	-2.80 -0.22%	-10.00 -0.85%	-0.30 -0.08%	-6.00 -0.33%	13.95 0.95%	-12.75 -0.71%	-106.25 -0.96%	-22.80 -1.32%	-9.50 -0.21%	7.20 2.91%

Hot Pursuit

Scrips, which has significant changes during the market hours.

Alembic Pharma gains after receiving USFDA nod for Betamethasone Valerate Foam

26-Aug-24 09:55Hrs IST

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam of Norvium Bioscience, LLC (Norvium).

Betamethasone valerate foam is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.

The company has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA.

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.

The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."

A Muthoot M George Enterprise